Reason for request
Because of uncertainties about the benefit of adding to AVASTIN to paclitaxel chemotherapy in metastatic breast cancer (see previous chapter), the Transparency Committee considers that the actual benefit provided by AVASTIN is low.
Clinical Added Value
|no clinical added value||
Given the current data, the Transparency Committee considers that AVASTIN does not provide an improvement in actual benefit (IAB level V) in the management of patients with metastatic breast cancer who are HER2 negative or who are not eligible for treatment with Herceptin.